Session 1 – A Fascinating Year of Biotech Innovation and Investment
Date: 24 July (Wednesday) 14:00 - 16:30 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom A
Chief Science Officer
Innovent Biologics, Inc.
Dr. Blanchard joined Innovent Biologics as CSO since January 2018.
Prior to joining Innovent Biologics, Dr. Blanchard was the Senior Vice President of Lilly China Drug Development and External Innovation and was responsible for development of all medicines for Lilly China, the delivery of innovation across all therapeutic areas, and the execution of the external drug development portfolio. He positioned Lilly to capitalize on the positive changes in the Chinese regulatory environment, and also worked closely with Lilly Asia Ventures to expand the China innovation ecosystem. His interests include discovering and developing medicines and the application of translational research principles to drug discovery.
He was a co-founder and a member of the Board of Directors of the Asian Cancer Research Group, a not-for-profit company focused on the generation and dissemination of genetic and clinical data on cancers of importance in Asia. Dr. Blanchard received a BS degree in chemistry in 1977, a PhD in Biochemistry in 1982, and an MD in 1985 from Indiana University.
Prior to coming to Eli Lilly and Company in 2000, he was a tenured Professor of Medicine and Biochemistry & Molecular Biology at Louisiana State University Health Sciences Center in Shreveport, LA.